Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, Campbell S, Civati G, Bourbigot B, Alves Filho G, Leone J, Garcia VD, Rigotti P, Esmeraldo R, Cambi V, Haas T, Jappe A, Bernhardt P, Geissler J, Cretin N. Vitko S, et al. Among authors: bourbigot b. Am J Transplant. 2004 Apr;4(4):626-35. doi: 10.1111/j.1600-6143.2004.00389.x. Am J Transplant. 2004. PMID: 15023156 Free article. Clinical Trial.
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H Jr, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T; 2306 and 2307 study groups. Tedesco-Silva H Jr, et al. Among authors: bourbigot b. Transpl Int. 2007 Jan;20(1):27-36. doi: 10.1111/j.1432-2277.2006.00414.x. Transpl Int. 2007. PMID: 17181650 Free article. Clinical Trial.
Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
Krämer BK, Neumayer HH, Stahl R, Pietrzyk M, Krüger B, Pfalzer B, Bourbigot B, Campbell S, Whelchel J, Eris J, Vitko S, Budde K; RADA2307 Study Group. Krämer BK, et al. Among authors: bourbigot b. Transplant Proc. 2005 Apr;37(3):1601-4. doi: 10.1016/j.transproceed.2004.09.026. Transplant Proc. 2005. PMID: 15866684 Clinical Trial.
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M. Charpentier B, et al. Among authors: bourbigot b. Transplantation. 2003 Mar 27;75(6):844-51. doi: 10.1097/01.TP.0000056635.59888.EF. Transplantation. 2003. PMID: 12660513 Clinical Trial.
Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study.
Frimat L, Cassuto-Viguier E, Charpentier B, Noël C, Provôt F, Rostaing L, Glotz D, Sraer JD, Bourbigot B, Moulin B, Lang P, Ducloux D, Pouteil-Noble C, Girardot-Seguin S, Kessler M. Frimat L, et al. Among authors: bourbigot b. Am J Transplant. 2006 Nov;6(11):2725-34. doi: 10.1111/j.1600-6143.2006.01535.x. Am J Transplant. 2006. PMID: 17049060 Free article. Clinical Trial.
Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B, Suwelack B, Ivens K, Arns W, Lhotta K, Bourbigot B, Budde K, Fischer W, Pietruck F; ERL2405-DE02 Study Group. Nashan B, et al. Among authors: bourbigot b. Transplant Proc. 2006 Nov;38(9):2856-9. doi: 10.1016/j.transproceed.2006.08.118. Transplant Proc. 2006. PMID: 17112848 Clinical Trial.
Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant.
Mourad G, Karras A, Kamar N, Garrigue V, Legendre C, Lefrançois N, Charpentier B, Bourbigot B, Pouteil-Noble C, Bayle F, Lebranchu Y, Mariat C, Le Meur Y, Kessler M, Moulin B, Ducloux D, Delahousse M, Lang P, Merville P, Chaouche-Teyara K, Rostaing L; French Myriade FR01 Study Group. Mourad G, et al. Among authors: bourbigot b. Clin Transplant. 2007 May-Jun;21(3):295-300. doi: 10.1111/j.1399-0012.2007.00660.x. Clin Transplant. 2007. PMID: 17488375 Clinical Trial.
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N. Glotz D, et al. Among authors: bourbigot b. Transplantation. 2010 Jun 27;89(12):1511-7. doi: 10.1097/TP.0b013e3181db09e4. Transplantation. 2010. PMID: 20386144 Clinical Trial.
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D; Simulect International Study Group. Lawen JG, et al. Transplantation. 2003 Jan 15;75(1):37-43. doi: 10.1097/00007890-200301150-00007. Transplantation. 2003. PMID: 12544868 Clinical Trial.
57 results